MoonLake Immunotherapeutics (MLTX) News
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.07+0.04 (+0.36%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MLTX news summary
We found 4 recent headlines mentioning MoonLake Immunotherapeutics (MLTX): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, MLTX is up 0.36% at $11.07. The most recent story, "MoonLake Immunotherapeutics Consensus Price Target Raised 10.66% to $35.55", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest MoonLake Immunotherapeutics headlines
- MoonLake Immunotherapeutics Consensus Price Target Raised 10.66% to $35.55The average one-year price target for MoonLake Immunotherapeutics (NASDAQCM:MLTX) (BMV:MLTX N) has been revised to $35.55 / share. This is an increase of 10.66% from the prior estimate of $32.13…Nasdaq
- MoonLake Reports Wider Q3 Loss At $79 Mln Following BLA Submission For Sonelokimab(RTTNews) - MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, released third quarter financial results on Wednesday, noting a wider net loss arising from increased operating…NasdaqMLTX, BF.A
- MoonLake Immunotherapeutics Reports Third Quarter 2026 Financial Results and BLA SubmissionMoonLake Immunotherapeutics reported its third quarter 2026 financial results and provided a business update. On September 30, 2026, the Company submitted a Biologics License Application to the U.S.…Nasdaq
- MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business UpdateZUG, Switzerland, November 4, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for…GlobeNewswire